Trial reportBMC research notes2015
Catatonia in Ugandan children with nodding syndrome and effects of treatment with lorazepam: a pilot study.
Trial report in BMC research notes, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02462109 (Catatonia in Ugandan Children With Nodding Syndrome and Effects of Treatment With Lorazepam), which is not on this map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Catatonia in Ugandan Children With Nodding Syndrome and Effects of Treatment With Lorazepam: A Pilot Study
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Prevalence of Catatonia and Its Moderators in Clinical Samples: Results from a Meta-analysis and Meta-regression Analysis.Schizophrenia bulletin · 2018Pooled it
- Doxycycline for the treatment of nodding syndrome: a randomised, placebo-controlled, phase 2 trial.The Lancet. Global health · 2024Trial
- Preliminary seroprevalence study of neurotropic virus antibodies in Nodding syndrome.eNeurologicalSci · 2022Article
- Nodding Syndrome: A Scoping Review.Tropical medicine and infectious disease · 2021Article
- Catatonia: Clinical Overview of the Diagnosis, Treatment, and Clinical Challenges.Neurology international · 2021Review
- Article
- Economic burden of the persistent morbidity of nodding syndrome on caregivers in affected households in Northern Uganda.PloS one · 2020Article
- Nodding syndrome: a concise review.Brain communications · 2020Review
- Unravelling the mysterious onchocerciasis-nodding syndrome link: new developments and future challenges.Annals of translational medicine · 2017Article
- Nakalanga Syndrome: Clinical Characteristics, Potential Causes, and Its Relationship with Recently Described Nodding Syndrome.PLoS neglected tropical diseases · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNodding syndrome (NS) is a severe neuropsychiatric syndrome of an unknown etiology affecting children and adolescents mostly in Eastern Africa. Symptoms of NS and catatonia seem to overlap. We investigated the presence and types of catatonic symptoms in NS and their response to one or two doses of lorazepam, the first-line treatment for catatonia.
methodsA cross-sectional descriptive study with systematic assessment of catatonia in 33 patients with NS using a modified version of the Bush Francis Catatonia Rating Scale. Sixteen patients met criteria for catatonia and were observed in an open and uncontrolled study to examine the effects of one or two doses of lorazepam in them.
resultsSixteen of 33 patients with NS had an average of 5 catatonia symptoms and met criteria for catatonia. The highest scores were found for mutism, staring, poor eating/drinking, stupor, and grimacing. Excitement, rigidity, negativism and impulsivity had lower scores. None of the children had echolalia or echopraxia. In 6 children, there was a reduction of more than 50% in catatonia ratings, representing a positive response to lorazepam. Three out of six children whose catatonia ratings did not change after the first dose, responded after administration of a second double dose. There were no unusual or critical side-effects.
conclusionsAbout half of a selected sample of children with NS met criteria for catatonia. Catatonia scores decreased in most patients after one or two doses of lorazepam. Larger, longer, and controlled studies are warranted to assess the prevalence of catatonia in NS and to assess the use of lorazepam in NS through its effects on catatonia.
trial registrationClinicalTrials.gov NCT02462109 Date of formal registration: June 2, 2015.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.